Characteristics of the 1390 patients included in this study
| Patient characteristic | No. (%) |
|---|---|
| Sex | |
| Female | 1286 (93) |
| Male | 104 (7) |
| Race | |
| Caucasian | 708 (51) |
| African-American | 550 (40) |
| Other | 132 (10) |
| Age (years) at SLE diagnosis | |
| <30 | 689 (50) |
| 30–44 | 466 (34) |
| 45–59 | 191 (14) |
| 60+ | 44 (3) |
| SLE duration (years) at cohort entry | |
| <1 | 565 (41) |
| 1–3 | 226 (16) |
| 3–6 | 193 (14) |
| 6+ | 406 (29) |
| No. of years at risk since SLE diagnosis | |
| 1–5 | 319 (23) |
| 5–10 | 319 (23) |
| 10–15 | 298 (21) |
| 15+ | 454 (33) |
| No. of cohort visits during which anticardiolipin and RVVT were measured | |
| 3–10 | 401 (29) |
| 10–19 | 318 (23) |
| 20+ | 671 (48) |
| SLE manifestations (based on ACR-11 criteria) | |
| Malar rash | 780 (56) |
| Discoid rash | 320 (23) |
| Photosensitivity | 797 (57) |
| Oral ulcers | 700 (50) |
| Arthritis | 1084 (78) |
| Serositis | 733 (53) |
| Renal | 665 (48) |
| Neurological | 188 (14) |
| Haematological | 994 (72) |
| Immunological | 1155 (83) |
| ANA | 1330(96) |
ACR, American College of Rheumatology; ANA, anti nuclear antibody; RVVT, Russell's viper venom time; SLE, systemic lupus erythematosus.